drugset / Trial / NCT07355283
IMM0306 in Combination With Lenalidomide vs Placebo in Combination With Lenalidomide in Patients With Relapsed/Refractory Follicular Lymphoma
RandomizedParallel-groupDouble-blindTreatment
Summary
This study is a randomized, controlled, double-blind, multicenter, phase III clinical study to evaluate the efficacy of IMM0306 (Amulirafusp Alfa)in combination with lenalidomide versus placebo in combination with lenalidomide in patients with Relapsed/Refractory Follicular lymphoma. Primary endpoints are Complete Remission Rate (CRR) and Progression-Free Survival (PFS).
Timeline
- Start
- 2026-02
- Primary completion
- 2028-07
- Completion
- 2030-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | IMM0306 | Protein / enzyme biologic | 2 mg/kg | Intravenous |
| Background | Lenalidomide | Other / unclassified | 20 mg | Oral |